Albaugh, BJ, Anderson, PO (1974) Peyote in the treatment of alcoholism among American Indians. Am J Psychiatry 131: 1247–1250.
Google Scholar | Crossref | Medline | ISI Ashrafioun, L, Bonadio, FA, Baik, KD, et al. (2016) Patterns of use, acute subjective experiences, and motivations for using synthetic cathinones (“bath salts”) in recreational users. J Psychoactive Drugs 48: 336–343.
Google Scholar | Crossref | Medline Barrett, FS, Bradstreet, MP, Leoutsakos, J-MS, et al. (2016) The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. J Psychopharmacol 30: 1279–1295.
Google Scholar | SAGE Journals | ISI Barrett, FS, Johnson, MW, Griffiths, RR (2015) Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol 29: 1182–1190.
Google Scholar | SAGE Journals | ISI Bevan, P, Bradshaw, C, Roberts, M, et al. (1974) The effect of microelectrophoretically applied mescaline on cortical neurones. Neuropharmacology 13: 1033–1045.
Google Scholar | Crossref | Medline Beyerstein, BL (2003) Hallucinogens: A Forensic Handbook. Academic Press.
Google Scholar Carhart-Harris, RL, Bolstridge, M, Rucker, J, et al. (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3: 619–627.
Google Scholar | Crossref | Medline | ISI Carstairs, SD, Cantrell, FL (2010) Peyote and mescaline exposures: A 12-year review of a statewide poison center database. Clin Toxicol 48: 350–353.
Google Scholar | Crossref Cattell, JP (1954) The influence of mescaline on psychodynamic material. J Nerv Ment Dis 119: 233–244.
Google Scholar | Crossref | Medline Clarke, PB, Giordano, AL, Cashwell, CS, et al. (2013) The straight path to healing: Using motivational interviewing to address spiritual bypass. J Couns Dev 91: 87–94.
Google Scholar | Crossref Cochin, J, Woods, L, Seevers, M (1951) The absorption, distribution and urinary excretion of mescaline in the dog. J Pharmacol Exp Ther 101: 205–209.
Google Scholar | Medline Cohen, S (1960) Lysergic acid diethylamide: Side effects and complications. J Nerv Ment Dis 130: 30–40.
Google Scholar | Crossref | Medline | ISI Darvesh, AS, Gudelsky, GA (2003) Activation of 5-HT2 receptors induces glycogenolysis in the rat brain. Eur J Pharmacol 464: 135–140.
Google Scholar | Crossref | Medline Dasgupta, A (2019) Abuse of Magic Mushroom, Peyote Cactus, LSD, Khat, and Volatiles. In: Critical Issues in Alcohol and Drugs of Abuse Testing. Elsevier, pp.477–494.
Google Scholar | Crossref Davis, AK, Barrett, FS, Griffiths, RR (2020a) Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. J Contextual Behav Sci 15: 39–45.
Google Scholar | Crossref | Medline Davis, AK, Barrett, FS, May, DG, et al. (2020b) Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry e203285.
Google Scholar Davis, AK, Barrett, FS, So, S, et al. (2021) Development of the psychological insight questionnaire among a sample of people who have consumed psilocybin or LSD. J Psychopharmacol. Epub ahead of print 9 January 2021. DOI: 10.1177/0269881120967878.
Google Scholar | SAGE Journals Davis, AK, Barsuglia, JP, Lancelotta, R, et al. (2018) The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. J Psychopharmacol 32: 779–792.
Google Scholar | SAGE Journals | ISI Davis, AK, So, S, Lancelotta, R, et al. (2019) 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. Am J Drug Alcohol Abuse 45: 161–169.
Google Scholar | Crossref | Medline Delgado, PL, Moreno, FA (1998) Hallucinogens, serotonin and obsessive-compulsive disorder. J Psychoactive Drugs 30: 359–366.
Google Scholar | Crossref | Medline Dobkin, M (1968) Trichocereus pachanoi—A mescaline cactus used in folk healing in Peru. Econ Bot 22: 191–194.
Google Scholar Drug Enforcement Administration (DEA) (2019) Drug Enforcement Administration, Department of Justice. Controlled Substances in Alphabetical Order. Available at: https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf.
Google Scholar Dunnell, T (2018) Drugs in Peru: The Laws of Legal and Illegal Possession. Available at: www.newperuvian.com/drugs-in-peru-legal-and-illegal/ (accessed 19 October 2018).
Google Scholar Epstein, K (2019) Oakland decriminalizes ‘magic mushrooms’ and other natural psychedelics. The Washington Post, 6 June, 2019.
Google Scholar Erowid (2009) The Flesh of God: Peyote and CannabisPeyote (exp55601). Avaliable at: www.erowid.org/exp/55601.
Google Scholar Erowid (2011) A Seminal Spiritual Event: An Experience with Mescaline (exp91450). Available at: www.erowid.org/exp/91450.
Google Scholar Erowid (2012) WhoAreYou. Accepting Death and Utter Ecstasy: An Experience with Mescaline (exp88982). Available at: https://erowid.org/experiences/exp.php?ID=88982.
Google Scholar Fox, J, Cashwell, CS, Picciotto, G (2017) The opiate of the masses: Measuring spiritual bypass and its relationship to spirituality, religion, mindfulness, psychological distress, and personality. Spiritual Clin Pract 4: 274.
Google Scholar | Crossref Frederking, W (1955) Intoxicant drugs (mescaline and lysergic acid diethylamide) in psychotherapy. J Nerv Ment Dis 121: 262–266.
Google Scholar | Crossref | Medline Garcia-Romeu, A, Davis, AK, Erowid, F, et al. (2019) Cessation and reduction in alcohol consumption and misuse after psychedelic use. J Psychopharmacol 33: 1088–1101.
Google Scholar | SAGE Journals | ISI Garcia-Romeu, A, Davis, AK, Erowid, E, et al. (2020) Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey. Front Psychiatry 10: 955.
Google Scholar | Crossref | Medline Garcia-Romeu, A, Kersgaard, B, Addy, PH (2016) Clinical applications of hallucinogens: A review. Exp Clin Psychopharmacol 24: 229.
Google Scholar | Crossref | Medline | ISI Griffiths, RR, Johnson, MW, Richards, WA, et al. (2011) Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology 218: 649–665.
Google Scholar | Crossref | Medline | ISI Griffiths, RR, Richards, WA, McCann, U, et al. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187: 268–283.
Google Scholar | Crossref | Medline | ISI Guttmann, E (1936) Artificial psychoses produced by mescaline. J Ment Sci 82: 203–221.
Google Scholar | Crossref Halpern, JH, Sherwood, AR, Hudson, JI, et al. (2005) Psychological and cognitive effects of long-term peyote use among Native Americans. Biol Psychiatry 58: 624–631.
Google Scholar | Crossref | Medline | ISI Halpern, S (1961) On the similarity between hypnotic and mescaline hallucinations. Int J Clin Exp Hypn 9: 139–149.
Google Scholar | Crossref | Medline Hartogsohn, I (2017) Constructing drug effects: a history of set and setting. Drug Sci Policy Law 3: 2050324516683325.
Google Scholar | SAGE Journals Hermle, L, Fünfgeld, M, Oepen, G, et al. (1992) Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol Psychiatry 32: 976–991.
Google Scholar | Crossref | Medline | ISI Jay, M (2019) Mescaline: A Global History of the First Psychedelic: Yale University Press.
Google Scholar | Crossref Johansen, P-Ø, Krebs, TS (2015) Psychedelics not linked to mental health problems or suicidal behavior: A population study. J Psychopharmacol 29: 270–279.
Google Scholar | SAGE Journals | ISI Johnson, MW, Garcia-Romeu, A, Cosimano, MP, et al. (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 0269881114548296.
Google Scholar Kapadia, GJ, Fayez, M (1970) Peyote constituents: Chemistry, biogenesis, and biological effects. J Pharm Sci 59: 1699–1727.
Google Scholar | Crossref | Medline Klüver, H (1926) Mescal visions and eidetic vision. Am J Psychol 37: 502–515.
Google Scholar | Crossref Knauer, A, Maloney, W (1913) A preliminary note on the psychic action of mescaline, with special reference to the mechanism of visual hallucinations. J Nerv Ment Dis 40: 425.
Google Scholar | Crossref Koelle, GB (1958) The pharmacology of mescaline and D-lysergic acid diethylamide (LSD). N Engl J Med 258: 25–32.
Google Scholar | Crossref | Medline Krebs, TS, Johansen, P-Ø (2013) Psychedelics and mental health: A population study. PLoS One 8: e63972.
Google Scholar | Crossref | Medline | ISI Kyzar, EJ, Collins, C, Gaikwad, S, et al. (2012) Effects of hallucinogenic agents mescaline and phencyclidine on zebrafish behavior and physiology. Prog Neuropsychopharmacol Biol Psychiatry 37: 194–202.
Google Scholar | Crossref | Medline | ISI Luke, D, Terhune, DB (2013) The induction of synaesthesia with chemical agents: A systematic review. Front Psychol 4: 753.
Google Scholar | Crossref | Medline McCabe, SE, West, BT, Jutkiewicz, EM, et al. (2017) Multiple DSM-5 substance use disorders: A national study of US adults. Hum Psychopharmacol 32: e2625.
Google Scholar | Crossref McLaughlin, JL (1973) Peyote: an introduction. Lloydia 36: 1–8.
Google Scholar | Medline MacLean, KA, Johnson, MW, Griffiths, RR (2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 25: 1453–1461.
Google Scholar | SAGE Journals | ISI Mason, NL, Mischler, E, Uthaug, MV, et al. (2019) Sub-acute effects of psilocybin on empathy, creative thinking, and subjective well-being. J Psychoactive Drugs 1–12.
Google Scholar Monte, AP, Waldman, SR, Marona-Lewicka, D, et al. (1997) Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives. J Med Chem 40: 2997–3008.
Google Scholar | Crossref | Medline Nichols, DE (2004) Hallucinogens. Pharmacol Therapeut 101: 131–181.
Google Scholar | Crossref | Medline | ISI Nichols, DE (2016) Psychedelics. Pharmacol Rev 68: 264–355.
Google Scholar | Crossref | Medline | ISI Nolte, KB, Zumwalt, RE (1999) Fatal peyote ingestion associated with Mallory-Weiss lacerations. West J Med 170: 328.
Google Scholar | Medline